Meeting
2016 Gastrointestinal Cancers Symposium
Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902—Comparison of administration interval in cetuximab treatment.
Authors
Tomohiro Kondo
KKR Tonan Hospital, Sapporo, Japan
Tomohiro Kondo , Satoshi Yuki , Yasuyuki Kawamoto , Yasushi Tsuji , Ayumu Hosokawa , Michio Nakamura , Osamu Muto , Takashi Kato , Ichiro Iwanaga , Atsushi Sato , Kazunori Eto , Kouichi Furukawa , Hideyuki Hayashi , Miki Tateyama , Yasuo Takahashi , Susumu Sogabe , Takuya Honda , Yuh Sakata , Yoshito Komatsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000004882
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 771)
DOI
10.1200/jco.2016.34.4_suppl.771
Abstract #
771
Poster Bd #
O2
Abstract Disclosures